Market Place
Sourcing Support
Hutchmed Announces Breakthrough Designation for Orpathys & Tagrisso
11 Dec 2024 //
GLOBENEWSWIRE
Govt asks manufacturers to cut price of 3 anti-cancer drugs
29 Oct 2024 //
ECONOMICTIMES
HUTCHMED Tagrisso Plus Orpathys High Response In Lung Cancer
16 Oct 2024 //
GLOBENEWSWIRE
FDA expands label for AZ`s Tagrisso in NSCLC indication
27 Sep 2024 //
FIERCE PHARMA
TAGRISSO Approved For Stage III EGFR-Mutated Lung Cancer
26 Sep 2024 //
BUSINESSWIRE
Black Diamond Announce BDTX-1535 Phase 2 Data In EGFRm NSCLC
23 Sep 2024 //
GLOBENEWSWIRE
Cellworks Predicts Chemo Benefit In EGFR-Mutant NSCLC
09 Sep 2024 //
BUSINESSWIRE
RYBREVANT Plus Lazertinib Shows Survival Trend In Lung Cancer
08 Sep 2024 //
GLOBENEWSWIRE
HUTCHMED To Present Clinical Data At ESMO And World Lung Cancer Conf
08 Sep 2024 //
GLOBENEWSWIRE
EU approves AstraZeneca’s Tagrisso as new 1st-line treatment for lung cancer
06 Jul 2024 //
PHARMABIZ
China approves AZ`s Tagrisso-chemo combo as first-line treatment
26 Jun 2024 //
REUTERS
Tagrisso granted Priority Review in the US for patients with unresectable
10 Jun 2024 //
PHARMABIZ
TAGRISSO Reduces Progression Risk By 84% In Unresectable EGFR+ NSCLC
02 Jun 2024 //
BUSINESSWIRE
AstraZeneca aims for $80 bln in total revenue by 2030
21 May 2024 //
REUTERS
Jury says AstraZeneca should pay Pfizer $107M+ over Tagrisso infringement
20 May 2024 //
ENDPTS
Pfizer wins $107.5M from AZ in US cancer drug patent trial
18 May 2024 //
REUTERS
AstraZeneca’s earnings surprise investors as cancer drugs fuel growth
26 Apr 2024 //
BIOPHARMADIVE
AstraZeneca beats revenue, profit estimates on resilient demand
25 Apr 2024 //
REUTERS
TAGRISSO demonstrated efficacy benefit in EGFR-mutated lung cancer
20 Feb 2024 //
BUSINESSWIRE
U.S. FDA approves AstraZeneca`s Tagrisso-chemo combo
17 Feb 2024 //
PRESS RELEASE
Kairos Doses First Patients in Phase 1 Trial of Lead Drug Candidate ENV105
16 Jan 2024 //
GLOBENEWSWIRE
AstraZeneca picks up a friend for Tagrisso in $40M upfront deal
02 Jan 2024 //
FIERCE BIOTECH
TAGRISSO reduced the risk of disease progression in the brain by 42%
21 Oct 2023 //
BUSINESSWIRE
ESMO: Should AZ worry about J&J`s Tagrisso head-to-head win?
17 Oct 2023 //
FIERCE PHARMA
AstraZeneca’s Tagrisso, chemotherapy combo granted speedy FDA review
17 Oct 2023 //
PRESS RELEASE
J&J’s challenge to AstraZeneca in lung cancer takes flight with PhIII PFS win
29 Sep 2023 //
ENDPTS
AZ`s Tagrisso combo shows edge, but survival data leave doubts
12 Sep 2023 //
BUSINESSWIRE
LianBio Announces First Patient Treated in Ph 1 Trial of SHP2 Inhibitor BBP-398
03 Aug 2023 //
GLOBENEWSWIRE
LianBio Announces Clinical Supply Agreement with AZ in China to Evaluate BBP-398
12 Jul 2023 //
GLOBENEWSWIRE
TAGRISSO achieved unprecedented survival in early-stage EGFR-mutated lung cancer
04 Jun 2023 //
BUSINESSWIRE
AZ`s Tagrisso plus chemo triumphs in EGFR-mutated lung cancer
18 May 2023 //
PRESS RELEASE
Adjuvant Tagrisso shows strong OS benefit in early lung cancer
10 Mar 2023 //
PRESS RELEASE
Genprex Receives Approval to Proceed PI Trial of REQORSA with Tagrisso
14 Dec 2022 //
PRNEWSWIRE
J INTS BIO, presentation of data of its Oral 4th Generation EGFR-TKI `JIN-A02`
15 Sep 2022 //
PRNEWSWIRE
TAGRISSO demonstrated 5.5-year disease-free survival in the adjuvant treatment
11 Sep 2022 //
BUSINESSWIRE
Merck to Highlight Data at ESMO with Potential for Impact on Cancer Patients
07 Sep 2022 //
BUSINESSWIRE
AstraZeneca Scores Japanese Approvals in NSCLC, gMG and Breast Cancer
26 Aug 2022 //
BIOSPACE
Tagrisso approved in Japan for the adjuvant treatment of patients
25 Aug 2022 //
PRESS RELEASE
Genprex to progress Phase I/II trial of non-small cell lung cancer therapy
16 Aug 2022 //
CLINICALTRIALSARENA
EQRx, in bid to compete, takes on AstraZeneca’s top seller in head-to-head trial
12 Aug 2022 //
BIOPHARMADIVE
HUTCHMED, AstraZeneca`s TAGRISSO Plus Savolitinib Demonstrated 49% ORR
08 Aug 2022 //
GLOBENEWSWIRE
Guardant Health & Blueprint Medicines present real-world data at IASLC 2022
08 Aug 2022 //
BUSINESS WIRE
AZ has defended Tagrisso from generics. But for how long?
27 Apr 2022 //
FIERCEPHARMA
Vivace Tx Highlights Strong Synergistic Activity for VT3989 + Osimertinib
11 Apr 2022 //
PRNEWSWIRE
Genprex Receives FDA FTD for REQORSA Immunogene Therapy + Keytruda in NSCLC
03 Jan 2022 //
BUSINESSWIRE
NICE recommends osimertinib for non-small cell lung cancer (NSCLC)
01 Dec 2021 //
EUROPEANPHARMACEUTICALREVIEW
Hutchmed, AZ begin phase III trial of Orpathys, Tagrisso combo in lung cancer
26 Nov 2021 //
PHARMABIZ
New Data on RYBREVANT+Lazertinib Show Early Activity in Patients with NSCLC
19 Sep 2021 //
PRNEWSWIRE
Ascentage Reports Data of Its Investigational Bcl-2/Bcl-xL Inhibitor Pelcitoclax
08 Sep 2021 //
PRNEWSWIRE
HUTCHMED and AstraZeneca Initiate SANOVO PIII Trial of ORPATHYS and TAGRISSO
08 Sep 2021 //
GLOBENEWSWIRE
Zydus Cadila receives USFDA tentative approval for Osimertinib Tablets
03 Jun 2021 //
BUSINESS-STANDARD
AZ’s Tagrisso approved for EGFR-positive NSCLC in the EU
01 Jun 2021 //
PMLIVE
EU clears Tagrisso for early-stage EGFR-mutated lung cancer
27 May 2021 //
PHARMATIMES
AZ` Tagrisso first to win MHRA approval under Project Orbis
07 May 2021 //
PHARMATIMES
AZ`s oncology head talks up Tagrisso, Imfinzi potential
30 Apr 2021 //
FIERCE PHARMA
Tagrisso moves closer towards EU approval for early-stage lung cancer
26 Apr 2021 //
PHARMATIMES
Tagrisso recommended for approval in the EU by CHMP for the adjuvant
26 Apr 2021 //
PRESS RELEASE
AZ`s EGFR inhibitor Tagrisso cuts relapse, death risks in patients chemotherapy
01 Feb 2021 //
ENDPTS
